Background: Pharmacokinetic (PK) and pharmacodynamic (PD) models are used in target-controlled-infusion (TCI) systems to determine the optimal drug administration to achieve a desired target concentration in a central or effect-site compartment. Our aim was to develop a PKePD model for propofol that can predict the bispectral index (BIS) for a broad population, suitable for TCI applications. Methods: Propofol PK data were obtained from 30 previously published studies, five of which also contained BIS observations. A PKePD model was developed using NONMEM. Weight, age, post-menstrual age (PMA), height, sex, BMI, and presence/absence of concomitant anaesthetic drugs were explored as covariates. The predictive performance was measured across young children, children, adults, elderly, and high-BMI individuals, and in simulated TCI applications. Results: Overall, 15 433 propofol concentration and 28 639 BIS observations from 1033 individuals (672 males and 361 females) were analysed. The age range was from 27 weeks PMA to 88 yr, and the weight range was 0.68e160 kg. The final model uses age, PMA, weight, height, sex, and presence/absence of concomitant anaesthetic drugs as covariates. A 35-yr-old, 170 cm, 70 kg male (without concomitant anaesthetic drugs) has a V 1 , V 2 , V 3 , CL, Q 2 , Q 3 , and k e0 of 6.28, 25.5, 273 litres, 1.79, 1.75, 1.11 litres min À1 , and 0.146 min À1 , respectively. The propofol TCI adminis-
Editor's key points
A new propofol pharmacokineticepharmacodynamic (PKePD) model was developed using bispectral index (BIS) as the targeted endpoint based on previously published data from 30 studies. The PKePD model predicted propofol concentrations and BIS for a diverse population, from neonates to the elderly and high-BMI individuals, for both anaesthesia and sedation. The model should likely be useful for target-controlled infusion in anaesthesia and sedation in population including a wide ranges of age and body weight.
Over the past three decades, numerous publications have described pharmacokinetic (PK) and pharmacodynamic (PD) models for predicting the time course of plasma and effectsite concentrations, and the relationship between concentration and effect of propofol, for numerous patient populations. Some of these models have been incorporated into infusion pumps and advisory displays 1 to guide propofol dosing and administration. 2e4 An important application of these models is target-controlled-infusion (TCI) systems that optimise propofol administration to achieve stable drug concentrations in plasma or an effect site associated with a clinically relevant drug effect rapidly. These systems are used in routine clinical practice and might play a beneficial role in patient outcomes. TCI systems rely on PK and PD models that are most reliable when used in patients with similar characteristics to those of the study population. Thus, clinicians must be aware of the demographic support of the models they utilise, and might have to switch models when caring for different patient populations (e.g. children, adults, and obese patients). We previously showed 5 that analysing data (PK only) from multiple studies and estimating a single model can result in more accurate covariate detection and better performance across groups with diverse ages and weights even when compared with specialised models with narrow covariate ranges. Similar results have been obtained for remifentanil. 6, 7 The single-model approach can also reduce uncertainty with regard to an appropriate TCI model 8 for a
given clinical situation. There is no published PKePD model for propofol with broad support for diverse age and weight groups.
Our aim was to develop a PKePD model for propofol with broad support, achieving good predictive performance balanced across diverse subgroups, over a wide range of age and size, from neonates to the elderly, and both obese and non-obese individuals. Estimating a PD model enables its use in effect-site targeted TCI applications, whereas our previous propofol PK model only enabled plasma-targeted TCI. In addition, propofol PK was analysed focusing on physiologically relevant covariates, avoiding the patient/volunteer distinction of our previous general-purpose propofol PK model. 5 With the final model, we compare propofol dosing for use in TCI applications targeting anaesthesia and sedation with dosing recommendations from the official propofol drug label. If these are similar, this suggests that the TCI application of the model with appropriate targets results in adequate anaesthetic and sedative depth, as recommended in the propofol dosing guidelines. For comparison, we performed similar simulations of TCI using other PKePD models used in commercial TCI systems.
Methods
For the PK model development, we applied previously published PK data 5 that were used for the development of a generalpurpose PK model for propofol. We expanded these with data from propofol PKePD studies where bispectral index (BIS) (Medtronic, Dublin, Ireland) data were available. In total, data from 30 studies ( Table 1 ) was used. All included studies obtained the necessary ethical committee approval, as declared in the original publications or by the contributing authors. From the available covariates, (postnatal) age, postmenstrual age (PMA), weight, height, sex, BMI, use of concomitant opioids or local anaesthetic drugs, and blood sampling site (arterial vs venous) were considered for potential relationships with model parameters. If PMA was not recorded, it was assumed to be 40 weeks longer than age. For some individuals, height was not recorded, so we assumed height was the average of other individuals of the same gender with weight within 5% of that of the individual with missing height data.
NONMEM version 7.3 (ICON Development Solutions, Ellicott City, MD, USA) was used for model estimation and evaluation using the first-order conditional estimation method with interaction. For calculations of model predictive performance, we used R (version 2.14.1) (R Foundation for Statistical Computing). 9 Some studies listed in Table 1 used TCI administration of propofol; this produces infusion profiles with frequent small changes in infusion rate, resulting in slow NONMEM execution. We combined sequential infusion records if they were separated by <1 s and infusion rates differed by <0.5 mg min
À1
. The two records were merged with the summed dose over the combined duration, until no dosing records could be combined. After the model development was completed, we estimated the final PK model with the non-reduced dosing records, and determined whether the estimated parameters differed significantly.
PK and PD analysis
A three-compartment mammillary PK model was used with volumes V 1 , V 2 , and V 3 ; elimination clearance CL; and intercompartmental clearances Q 2 and Q 3 . We assumed that the recorded propofol concentrations represent plasma concentrations, predicted by the concentration in the central compartment V 1 . The residual error was additively distributed in the logarithm of the observed and predicted concentrations. For model development, we used a reference individual 10 (a 70 kg male, 35 yr of age, and 170 cm tall). The model parameters were assumed to be either log-normally distributed or constant across the population. We did not consider PK models more complex than the threecompartment models. The first model tested scaled all parameters linearly with weight. 11 We explored allometric scaling for model parameters, a method related to Kleiber's law 12 with a theoretical foundation in biology. 13 The scaling exponents used were the The PD measure BIS was modelled using a sigmoidal E max model driven by an effect compartment concentration C e . The effect compartment was connected to the central compartment by a first-order rate constant (k e0 ). The PD equations were:
where C is the concentration in V 1 , and drug effect corresponds to the fraction of the maximal drug effect achieved, varying between 0 and 1 (between 0% and 100%). C e50 is the C e associated with 50% drug effect, BIS baseline is the BIS measure in the absence of drug effect, g is the steepness of the concentration vs BIS relation, and ε represents additive residual error. Other levels of drug effect can be denoted, such as the drug effect of 0.1 (10%) may be referred to as C e10 . BIS signal processing delay was estimated from the data, with a fixed minimum of 15 s. No distinction was made between the various BIS monitor software versions used. During PD model estimation, individual PK parameters were fixed to those estimated from the PK model estimation, known as the sequential method. 16, 17 Individual variability h values obtained from NONMEM estimation were used to identify significant covariates that were subsequently tested for inclusion in the model. We required the corrected Akaike information criterion (AIC) to decrease at least 20 for inclusion of a parameter in the model, and also required improvement in predictive performance measured using the method described as follows. Model modifications that decreased or left unchanged the number of parameters only required a decrease in AIC. For the final PK and PD models, likelihood profiles were generated for estimated model parameters. Uncertainty was expressed as upper and lower 99% confidence limits, estimated via spline interpolation of the likelihood profiles. These were determined by the increase/decrease in each parameter required to increase the NONMEM objective function by 6.63.
Performance error, bias, and precision
During the PK model development, we evaluated bias and precision using the logarithmic prediction-error measure:
For comparison with other PK models, we used the more widely applied performance error 19 (PE PK ) and absolute performance error (APE PK ) as:
For BIS observations, we used performance error calculations more suitable for additive error models:
The LE and PE measures indicate bias, and the ALE and APE measures indicate precision. To summarise these, we report the median values, prefixing the measure with Md. We considered MdPE PK <10e20% and MdAPE PK of 20e40% to indicate clinically acceptable performance. 20, 21 The performance error measures of the final model were compared with previously published propofol models: a general-purpose PK model we previously published, 5 adult models published by Schnider and colleagues, 22 Marsh and colleagues, 23 Cortínez and colleagues, 24 and White and colleagues, 25 and paediatric models published by Kataria and colleagues, 26 Short and colleagues, 27 Rigby-Jones and colleagues, 28 Rigby-Jones and colleagues (multicentre), 29 and the 'Paedfusor' model.
30,31
Estimating PK predictive performance
At each step in model development, we estimated the ability of the model to predict out-of-sample observations (i.e. observations not included in the estimation data set). For this, we used repeated two-fold cross validation. Before analysis, individuals were randomly partitioned into equally sized groups: D1 and D2. The model was estimated using D1, and the parameters then held constant and used to predict D2 using only individual covariates (h fixed to 0). The process was then repeated, exchanging D1 and D2. Predictions for D1 and D2 were combined to obtain a complete set of predictions. To reduce sampling variability caused by random partitioning, this process was repeated twice, obtaining two predictions for every observation. This expanded set of predictions was used for measures of out-of-sample bias and precision.
To ensure that the model development was not dominated by the largest subgroup, we analysed five subgroups separately: young children (age <3 yr), children (3 age <18 yr), Anaesthesia targets in children, adults, and the elderly Simulations of anaesthesia TCI for (non-obese) children, adults, and the elderly were performed using the final PKePD model targeting an effect-site concentration equal to the ageadjusted C e50 . Children of 5-yr-old (18 kg and 109 cm) and 10-yr-old (32 kg and 139 cm) were simulated. Adults (35 and 70 yr) were assumed to have 70 kg weight and 170 cm height. We also performed TCI simulations using the PKePD models incorporated into the Diprifusor 33 (plasma targeting) and by Schnider and colleagues 22 (effect-site targeting). For these models, only adults were simulated, and we used a target concentration of 4 mg ml À1 , which is the default concentration in the Diprifusor system.
Anaesthesia targets in obese adults
For simulation of anaesthesia TCI for obese adults, we assumed an age of 35 yr, height of 170 cm, and varied weight to achieve BMI values of 30e50. The target effect-site concentration was the same as for non-obese individuals, the age-adjusted C e50 . For the Diprifusor PK and Schnider and colleagues 22 PKePD models, the target concentration was 4 
MAC sedation in children, adults, and the elderly
To explore the TCI targeting sedation for children, adults, and the elderly, we performed simulations of TCI targeting the C e10 (i.e. 10% drug effect). This target was chosen subjectively because it would result in reduced drug effects and administration compared with anaesthesia. We compared drug administration with dosing recommendations for MAC sedation.
Results
In the PK analysis, there were 15 433 observations (11 530 arterial and 3903 venous) from 1033 individuals (672 males and 361 females) with an age range from 27 weeks PMA to 88 yr, and a weight range from 0.68 to 160 kg. For the defined subgroups, PK data from 71 young children, 128 children, 628 adults, 89 elderly, and 121 high-BMI individuals were analysed. For the PD analysis, there were 28 639 BIS observations from 122 individuals (56 males and 66 females) with an age range from 3 to 74 yr and a weight range from 15 to 141 kg. For the defined subgroups, PD data from 28 young children, 64 adults (including elderly), and 30 high-BMI individuals were analysed. The PK and PD observations are shown in Figure 1 , and demographic information is shown in Supplementary  Figure S1 . Height information was missing for 108 individuals, for whom the estimated height was used for FFM and BMI calculations.
PK model development
The PK model development process for the final model is shown in Supplementary Table S1 , and a detailed explanation of the steps in PK model building is included in Appendix 1. Briefly, the model incorporates allometric scaling, compartmental allometry, and a maturation model 35 for CL based on PMA. Peripheral volume V 2 declines with age, and CL and V 3 decline with age only when concomitant anaesthetic drugs are used. Parameter V 1 scales to an E max function with weight. In females, CL is higher, and a slow-maturation function influences Q 3 to increase with age whilst Q 2 decreases. Peripheral volume V 3 scales with FFM. The residual error varies across individuals. Some model parameters reflect arterialevenous differences. Estimating the final model using the non-reduced dosing records caused longer estimation times, but the final parameter estimates were within the P<0.05 confidence limits of the (reduced data) final PK model. The equations of the final model are:
The symbols Q 1 eQ 18 are estimated model parameters, and h 1 eh 7 are random variables representing interindividual variability. The estimated model parameters and their uncertainty are shown in Table 2 . AGE, PMA, and WGT represent the age (yr), PMA (weeks), and weight (kg), respectively. Symbols with the subscript ref are calculated for the reference individual. The symbol ε represents residual observation error in the log domain with a variance fixed to 1. The model diagnostic plots, complete PK data set, NONMEM code for the final model, and likelihood profiles can be found in Figure 2 , Supplementary Digital Content S1, Supplementary Digital Content S2, and Supplementary Figure S2 , respectively. From the model diagnostic plots, there is some upward bias for very early samples. This is likely because of our model lacking front-end kinetics effects. 18, 36 Some under-prediction for very late samples is also evident, but we were unable to reduce this without compromising the overall performance.
PK prediction-error comparison
The final PK model was compared with published propofol PK models, shown in Supplementary Table S2 . For both estimated (in-sample) and cross-validated (out-of-sample) predictions, the final PK model performed better than, or very similarly to, previously published models. The predictive performance of the final model was judged as likely to be clinically acceptable for all subgroups.
PD model development
Only three individuals with PD data were >70 yr old, so these were combined with the adult subgroup. The models evaluated during PD model development are shown in Supplementary  Table S3 , and a detailed explanation of the steps in PD model building is included in Appendix 2. Briefly, C e50 was found to decrease with age, whilst delay was found to increase with age. The parameter k e0 was found to be higher when the PK samples were venous. Residual error varied across individuals, and an asymmetric PD curve was found to improve the model fit. The allometric scaling of k e0 improved the extrapolation properties of the model without significantly degrading the model fit. The summarised equations of the final models are:
$expðh2Þ
for C e C e50 
The symbols Q 1 eQ 9 represent the estimated model parameters, and h 1 eh 3 are random variables representing interindividual variability. The estimated parameter values are shown in Table 3 . The symbol ε represents the additive residual observation error with a variance fixed to 1. The model diagnostic plots, complete PD data set, NONMEM code for the final model, and likelihood profiles can be found in Figure 3 
TCI simulations
For the final PKePD model, the relationship between effectsite concentration and predicted BIS, and the relationship between age and effect-site concentration for 50% and 10% drug effect (C e50 and C e10 ) are shown in Figure 4 . For anaesthetic concentration targets, we assumed the presence of concomitant anaesthetic techniques (e.g. opioids or local anaesthesia), whereas for sedation targets we assumed their absence. For anaesthesia targets of the C e50 , the expected BIS value would be 93$(1e0.5)¼47, whilst for MAC sedation targets of the C e10 it would be 93$(1e0.1)¼84. Because C e50 and C e10 vary with age, the specific target concentration depends on age.
Anaesthesia targets in children, adults, and the elderly Figure 5 shows the results from TCI simulations targeting the C e50 for (non-obese) children, adults, and elderly individuals using the final PKePD model. Maintenance infusions are shown for illustrative individuals. The initial dose matches well with induction dosing recommendations (shaded areas) across a wide age range, with smooth interpolation across age ranges. The maintenance infusion rates are also within or close to recommendations. Figure 6 shows the propofol administration with the Diprifusor PK and Schnider and colleagues 22 PKePD models targeted to 4 mg ml
À1
. For both models, induction doses are smaller than recommended for 18e55-yr-old individuals, but closer to recommendations in the elderly. The maintenance infusion rates are higher than recommended for young adults and the elderly. Both the Diprifusor and Schnider and colleagues 22 models require target adjustments depending on the patient group (young vs elderly) and over time (induction vs maintenance) for propofol administration to be close to recommendations. Figure 7 shows the results from the TCI simulations for obese (BMI >30) adults for the final PKePD model. The propofol administration matches well with anaesthesia induction and maintenance dosing recommendations when these are corrected using the equation of Servin and colleagues. 34 Diprifusor initial doses are lower than recommended for BMI of~30, and the dose (per kilogram) is not affected by changes in BMI. In contrast, the equation of Servin and colleagues 34 suggests that a lower (per kilogram body weight) initial dose is required as BMI increases into obesity. The maintenance infusion rates are higher than recommended in this group. The Schnider and colleagues 22 model yields lower than the recommended initial doses for obese individuals, <1 mg kg
Anaesthesia targets in obese adults

À1
, and higher than the recommended maintenance infusion rates. For this group, both the Diprifusor and Schnider and colleagues 22 models require target adjustments depending on the patient group (obese vs non-obese) and over time (anaesthesia vs maintenance) for propofol administration to match recommendations.
MAC sedation in children, adults, and the elderly Figure 8 shows the results from the TCI simulations of the final PKePD model targeting C e10 (i.e. effect-site concentrations associated with 10% drug effect). The initial dose and maintenance infusion rates correspond well with recommendations for MAC sedation.
Discussion
We developed a three-compartment PK model and effect-site sigmoidal PD model to predict propofol concentrations and BIS values for broad populations of individuals. The covariates of the PK model used to predict arterial concentrations were age, weight, height, and sex. PMA is also necessary for children younger than 5e6 months. Some parameters differ when concomitant anaesthetic drugs were used, such as opioids or local anaesthetics. The predictive performance of the PK model was good for all subgroups considered, and was generally better than that of previously published models. The covariates of the PD model were age and weight. Increasing age is associated with increased propofol sensitivity (decreased C e50 ) and increased lag time of the BIS signal. Residual error 0.463 76.7
The coefficient of variation is reported as:
We found that, when targeting C e50 , the final PKePD model results in propofol administration close to recommendations for anaesthesia in children, adults, and the elderly. The C e50 target would be expected to achieve a BIS value of 47, which is in the commonly clinically applied range of 40e60 for anaesthesia. For obese adults, the same C e50 target results in propofol administration matching recommendations for anaesthesia, provided these are adjusted according to the equation of Servin and colleagues. 34 In contrast, TCI using the Diprifusor or
Schnider and colleagues 22 model requires target adjustments depending on the patient group (adult vs elderly and obese vs non-obese) and over time (induction vs maintenance) for propofol administration to be close to recommendations. We showed that, when targeting C e10 , the final PKePD model results in propofol administration close to recommendations for MAC sedation. However, the BIS predictions of the final model may be biased in this range, because none of the data used in the development of the PKePD model were derived from studies targeting sedation.
The good agreement between propofol administration determined by the final PKePD model and recommendations can be seen as validation of the PKePD model. The dose recommendations were developed independently, but achieve presumably similar clinical results, namely, clinically adequate levels of anaesthesia or sedation. This concordance suggests that the PKePD model will be clinically useful when targeted to clinically relevant drug-effect levels, because propofol administration amounts and rates remain in a range likely to be familiar to clinicians. Of course, inter-individual variability and diverse clinical conditions also influence the appropriate dose, and thus TCI targets as well. For example, cardiac patients are recommended to receive an induction dose of 0.5e1.5 mg kg
À1
, which is considerably lower than for (non-cardiac) adults. Thus, with the current PKePD model, targets lower than C e50 are necessary for propofol administration to be close to recommendations for cardiac patients. values is not really valid, because the specific value depends on the PK, and the PK of our model differs from that of the Residual error 0.230 50.9
Drug transport to the effect site
The coefficient of variation is reported as: children, and Chidambaran and colleagues 40 found a value of 0.61 min À1 for severely obese adolescents. When incorporating our model in a TCI algorithm, arterial concentrations should be used for both PK and k e0 .
Concomitant opioid administration
We found an association between age and opioid sensitivity, as elimination clearance CL and distribution volume V 3 decrease with age when concomitant anaesthetic adjuvant drugs were applied (e.g. opioids or local anaesthetics). For opioids, decreased liver blood flow caused by opioid-induced cardiovascular depression is a possible mechanism. Midazolam has been shown to reduce propofol CL and inter-compartmental clearances. 41 Propofol interaction studies show additivity with remifentanil, 42, 43 which might be explained as reduced propofol CL and V 3 in the presence of opioids. When concomitant anaesthetic adjuvant drugs are applied, the PK model only indicates their presence or absence. For opioids especially, it seems obvious that the applied dose and achieved concentrations would play a role in a more physiological model. Unfortunately, precise dosing information for these additional drugs is absent in the data we analysed, so we cannot construct a more detailed model at this time. With the current approach, the model may not perform ideally when opioid administration is substantially greater than in the studies considered. In this situation, lower propofol administration and lower degrees of hypnosis are likely appropriate to avoid excessive anaesthetic depth. 44 This can be achieved by lowering the effect-site concentration or drugeffect targets. Despite its simplicity, our current approach has a better physiological basis than the distinction between patients vs healthy volunteers used in the general-purpose PK model we developed previously. 5 The apparent difference in propofol PK between patients and volunteers might be explained by the lack of supplemental anaesthetic drug administration in healthy volunteer studies.
Maturation
We found that a maturation model for CL based on PMA was a beneficial component of the model. The biological processes underlying propofol clearance appear to be immature in very young/small individuals. The use of a sigmoidal function to represent maturation has been suggested. 14 the recommended induction for adults, but similar in the elderly. For both models, the maintenance infusion rates are higher than the recommended in adults and the elderly. PD, pharmacodynamic; PK, pharmacokinetic.
increases as maturation progresses. This might reflect changes during growth where total body water decreases as a percentage of FFM with age and percentage body fat increases rapidly in infancy, but slowly decreases into adolescence.
46
Allometric scaling
We found that allometric scaling and compartmental allometry were beneficial for model performance, as was also found for remifentanil. 6 This approach avoids the James lean-bodymass equation, which is used in the Schnider and colleagues 22 and other models, and avoids its paradoxical behaviour in obese individuals.
47
Our PD model applies allometric scaling to k e0 , scaling it to (WGT/70) À0.25 . Whilst this has been considered before, 6, 48 we found that it results in more reasonable model characteristics for children, even though it did not improve the model fit. Our approach was to choose the most useful model consistent with the data.
Drug-effect targeting
In the PD model, there is a one-to-one relationship between drug effect and BIS values. So, whilst we denote the C e50 for anaesthesia and C e10 for MAC sedation as TCI targets, these can equivalently be given as a percentage drug effect (50% or 10%) or as target BIS values (47 or 84). Allowing clinicians to target drug-effect percentages or BIS values directly may have clinical advantages. This approach can compensate automatically for the considerable non-linearity in propofol PD. Verifying this requires further study.
Limitations of the study
This study has several limitations. First, the PKePD model was not prospectively evaluated; this should be done to evaluate its safety and efficacy. Second, for BIS observations, only one study in children was analysed, adolescents 12e19 yr are absent, and only three individuals older than 67 yr were analysed. Thus, the PD model has the weakest support in children and the elderly, and no support in young children and adolescents. Third, the three-compartment PK model shows some bias for late samples, indicating that terminal elimination is incorrectly modelled. Adding a fourth PK compartment could solve this problem, but we do not consider these models here. Fourth, during PK model development, we evaluated the predictive performance by averaging MdALE measures over subgroups. This measure might not be appropriate for every application. Fifth, the BIS signal has PK delays in the biophase in addition to processing and smoothing delays. Other clinically important PD responses, such as haemodynamic and respiratory changes, result from propofol actions on different systems and likely involve different lag times and rate constants. A propofol infusion profile optimal for BIS may not be optimal for other responses. One could criticise our simulations of the Diprifusor and Schnider and colleagues 22 PKePD models targeting 4 mg ml À1 as unrealistic, as in clinical practice, drug administration is 'titrated to effect' for each individual. This titration would also be necessary to individualise propofol administration when using the final PKePD model. However, for the Diprifusor and Schnider and colleagues 22 models, we show that no single target results in propofol administration matching recommendations, and target adjustments are likely necessary depending on the patient's age or obesity and over time as well. These target adjustments are additional mental and physical workload for the clinician, increasing the risk of subjectivity and errors. It seems reasonable to expect that fewer target adjustments would be necessary with the final PKePD model, because covariate adjustment and time-related factors seem better handled. However, this must be experimentally verified.
We created a PKePD model for propofol with support from a diverse population, from neonates to the elderly and high-BMI individuals. The model shows good PK predictive performance that is generally better than existing models. When using this PKePD model to target C e50 , propofol administration matches well with recommendations for anaesthesia in children, adults, elderly, and obese individuals. Targeting C e10 results in propofol administration matching well with recommendations for MAC sedation. This promotes confidence that the final PKePD model will be useful in clinical TCI applications. Prospective clinical evaluation is required to determine its safety and efficacy.
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